1. Home
  2. RGCO vs SGMT Comparison

RGCO vs SGMT Comparison

Compare RGCO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RGC Resources Inc.

RGCO

RGC Resources Inc.

HOLD

Current Price

$21.50

Market Cap

224.8M

Sector

Utilities

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.95

Market Cap

238.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGCO
SGMT
Founded
1912
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
224.8M
238.7M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RGCO
SGMT
Price
$21.50
$5.95
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.71
AVG Volume (30 Days)
11.8K
582.4K
Earning Date
02-09-2026
11-13-2025
Dividend Yield
4.08%
N/A
EPS Growth
11.26
N/A
EPS
1.29
N/A
Revenue
$95,334,212.00
N/A
Revenue This Year
$6.03
N/A
Revenue Next Year
$2.73
N/A
P/E Ratio
$16.53
N/A
Revenue Growth
12.63
N/A
52 Week Low
$19.06
$1.73
52 Week High
$23.82
$11.41

Technical Indicators

Market Signals
Indicator
RGCO
SGMT
Relative Strength Index (RSI) 37.49 39.65
Support Level $22.49 $5.92
Resistance Level $22.49 $6.33
Average True Range (ATR) 0.67 0.34
MACD -0.21 0.03
Stochastic Oscillator 6.38 16.74

Price Performance

Historical Comparison
RGCO
SGMT

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: